Abstract

AIDS: Although there have been great strides in AIDS research, there is no major development on the horizon that is capturing the attention of the press. However, there are significant developments being made in a number of areas. Current antiretroviral treatments are leading to declines in AIDS deaths and infections in the United States and studies are leading to a greater understanding of treatment failures and the role of compliance and adherence. Three new antiretrovirals are available in expanded access programs: abacavir (1592), efavirenz (Sustiva, DMP-266), and adefovir dipivoxil (Preveon, bis-POM PMEA). New treatment approaches will deal with restoring immune function, using vaccines to prevent HIV and opportunistic infection, and developing more antiretrovirals to combat the disease. The role of managed care and providing treatment to the uninsured and underinsured are also issues to be addressed in the coming year.